INSMED Inc — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Insmed reported Q3 2026 total revenues of $524.4M (+268% YoY), driven by BRINSUPRI $400.1M (+29% sequential) and ARIKAYCE $124.4M (+9% YoY). The company raised full-year 2026 guidance: BRINSUPRI to $1.35–1.4B (from $1.25–1.4B) and ARIKAYCE to $460–470M (from $450–470M). Cash position ~$1.1B; company expects cash flow positivity in 2027. Pipeline: TPIP Phase 3 studies progress (35% enrolled in PALM-ILD); INS1033 Phase 1 active; INS1201 fully enrolled; INS1202 enrolling. Japan launch of BRINSUPRI approved August 2026, launched October 2026; ARIKAYCE sNDA granted priority review (PDUFA January 28, 2027).
Why this rating
Strong commercial execution and upward guidance revision are real but modest relative to $21.1B market cap. Pipeline progress routine for stage. Moderate significance.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.